Key Principles and Recommended Regimens for First-line Antiretroviral Therapy

  • Author: Paul E. Sax, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 10/5/18 (What's New)

Summary

  • The phase III noninferiority trial DRIVE-FORWARD compared doravirine vs ritonavir-boosted darunavir, each with 2 NRTIs, in treatment-naive adults[Molina 2018]
    • Doravirine plus 2 NRTIs was found to be noninferior to ritonavir-boosted darunavir plus 2 NRTIs at Week 48 by the primary endpoint of proportion achieving HIV-1 RNA levels < 50 copies/mL (FDA snapshot algorithm)
    • Doravirine was associated with a more favorable lipid profile vs ritonavir-boosted darunavir at Week 48

Action required